BERLIN--(BUSINESS WIRE)--Regulatory News: TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company focused on developing novel therapies for treatment of cancer by ...

Please provide your email address to receive an email when new articles are posted on . DESTIN, Fla. — Inflammatory arthritis as a result of immune checkpoint cancer therapy remains a pressing ...

ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced positive results from its ANKTIVA ...

Among modern cancer therapies, immune checkpoint inhibitors (ICI) are among the most successful treatment methods. These ...

Initiation of phase 1 portion of the trial planned in 2H 2026-Phase 2 portion of the trial will initiate development of the elraglusib tablet in ...

Please provide your email address to receive an email when new articles are posted on . The mechanisms governing immune-related adverse events resulting from checkpoint inhibition therapy for cancer ...

With star checkpoint inhibitors like Keytruda and Opdivo now sporting subcutaneous formulations, GSK has struck a deal aimed ...

ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that the Saudi Food and Drug ...

The concept of immunotherapy or boosting the body’s immune system to target tumors was first practically applied in the early ...